Literature DB >> 18154212

Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.

Edith P Mitchell1, Roman Perez-Soler, Eric Van Cutsem, Mario E Lacouture.   

Abstract

This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition. Such effects include papulopustular reactions, xerosis, pruritus, fissures, nail changes, hair changes, telangiectasias, hyperpigmentation, and mucositis. Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18154212

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


  15 in total

Review 1.  Biological agents in gastrointestinal cancers: adverse effects and their management.

Authors:  Nivedita Arora; Arjun Gupta; Preet Paul Singh
Journal:  J Gastrointest Oncol       Date:  2017-06

2.  Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

Authors:  M Fakih; M Vincent
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

3.  Comparison of gefitinib-induced skin adverse reactions (SAR) in C57BL/6 and FVB/N mice.

Authors:  Yali Zhang; Yalei Wang; Ziwei Chen; Shuo Cheng; Chengcheng Ding; Jiani Zhang; Tiantian Peng; Weihang Chen; Dingyang Zhang; Yan Tan; Xu Wang; Ruijuan Dong; Miao Jiang; Qian Hua
Journal:  Toxicol Res (Camb)       Date:  2021-03-11       Impact factor: 3.524

4.  Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.

Authors:  Shaad E Abdullah; Missak Haigentz; Bilal Piperdi
Journal:  Chemother Res Pract       Date:  2012-09-11

5.  Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.

Authors:  G Habl; K Potthoff; M F Haefner; A Abdollahi; J C Hassel; E Boller; M Indorf; J Debus
Journal:  BMC Cancer       Date:  2013-07-15       Impact factor: 4.430

Review 6.  Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy.

Authors:  Ulrich Keller; Nikolas von Bubnoff; Christian Peschel; Justus Duyster
Journal:  J Cell Mol Med       Date:  2010-02-16       Impact factor: 5.310

Review 7.  Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.

Authors:  Brian A Baldo
Journal:  Oncoimmunology       Date:  2013-10-17       Impact factor: 8.110

8.  Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.

Authors:  B Melosky; R Burkes; D Rayson; T Alcindor; N Shear; M Lacouture
Journal:  Curr Oncol       Date:  2009-01       Impact factor: 3.677

Review 9.  KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.

Authors:  Ahmad D Siddiqui; Bilal Piperdi
Journal:  Ann Surg Oncol       Date:  2009-11-20       Impact factor: 5.344

10.  Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.

Authors:  Daanish Hoda; George R Simon; Christopher R Garrett
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.